IMUC


Roth Capital Maintains Buy On ImmunoCellular Following 3Q:14 Update

Roth Capital analyst Joseph Pantginis maintained a Buy rating on ImmunoCellular Therapeutics (NYSE:IMUC) with a price target of $3.00, following the company’s third-quarter …

Maxim Group Maintains Buy On ImmunoCellular Following Agreement With The California Institute

In a research report issued today, Maxim Group analyst Jason Kolbert maintained a Buy rating on ImmunoCellular Therapeutics (NYSE:IMUC) with a $4 price …

Roth Capital Maintained Buy On ImmunoCellular As Pipeline Expands

In a research report issued yesterday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on ImmunoCellular Therapeutics (OTCBB:IMUC) with a $3 price …

Roth Capital Reiterates Buy On ImmunoCellular Following Development Update

In a research report issued today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on ImmunoCellular Therapeutics (NYSE:IMUC) with a $3 price target, …

Roth Capital Maintains Buy On ImmunoCeulluar Following 2Q14 Results

In a research note published August 8th, Roth Capital analyst Joseph Pantginis maintained a Buy rating on ImmunoCellular Therapeutics (IMUC) with a $3 …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts